NHI.no
Annonse
Informasjon, tilstand

Helvetesild, herpes zoster

Helvetesild gir ubehag og smerter som kløe, prikking og svie. Utslettet kan bryte ut samtidig med smertene eller komme etterpå. Personer med helvetesild kan smitte andre med vannkopper.

Bildet viser utslett ved helvetesild.

Sist oppdatert:

18. mars 2024

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Herpes zoster . Referanselisten for dette dokumentet vises nedenfor

  1. Kofoed K, Rønholt F, Gerstoft J, Sand C. Herpes zoster: klinik, diagnostik og behandling. Ugeskr Læger 2011; 173: 114. Ugeskrift for Læger
  2. Saguil A, Kane S, Mercado M, Lauters R. Herpes zoster and postherpetic neuralgia: Prevention and management. Am Fam Physician 2017 Nov 15;96(10):656-663. Pmid: 29431387 PubMed
  3. Fashner J, Bell AL. Herpes zoster and postherpetic neuralgia: prevention and management. Am Fam Physician 2011; 83: 1432-7. American Family Physician
  4. Johnson BH, Palmer L, Gatwood J, et al. Annual incidence rates of herpes zoster among an immunocompetent population in the United States. BMC Infect Dis. 2015;15:502. PubMed
  5. Gnann JW, Whitley RJ. Herpes zoster. N Engl J Med 2002; 347: 340-6. PubMed
  6. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352: 2271-84. New England Journal of Medicine
  7. Wang Y-P, Liu C-J, Hu Y-W, et al. Risk of cancer among patients with herpes zoster infection: a population-based study. CMAJ 2012. doi:10.1503/CMAJ.120518 DOI
  8. Gebo KA, Kalyani R, Moore RD, Polydefkis MJ. The incidence of, risk factors for, and sequelae of herpes zoster among HIV patients in the highly active antiretroviral therapy era. J Acquir Immune Defic Syndr 2005; 40: 169. PubMed
  9. Forbes HJ, Bhaskaran K, Thomas SL, et al. Quantification of risk factors for herpes zoster: population based case-control study. BMJ 2014; 348: g2911. BMJ (DOI)
  10. Wang YP, Liu CJ, Hu YW, et al. Risk of cancer among patients with herpes zoster infection: a population-based study. CMAJ 2012 Oct 16; 184(15): E804-9. PMID: 22988158. PubMed
  11. Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. Clin Infect Dis 2007; 44 Suppl 1: S1.
  12. Helgason S, Petursson G, Gudmundsson S, Sigurdsson JA. Prevalence of post-herpetic neuralgia after a first episode of herpes zoster: a prospective study with long term follow up. BMJ 2000; 321: 794-6. PubMed
  13. Jumaan AO, Yu O, Jackson LA, et al. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J Infect Dis 2005; 191: 2002. PubMed
  14. Yawn BP, Saddier P, Wollan PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007; 82: 1341. PubMed
  15. Albrecht MA. Epidemiology, clinical manifestations, and diagnosis of herpes zoster. UpToDate, last updated Jun 20, 2022. www.uptodate.com
  16. Albrecht MA. Treatment of herpes zoster in the immunocompetent host. UpToDate, last updated Mar 11, 2020. Siden lest 30.3.2023. www.uptodate.com
  17. Werner RN, Nikkels AF, Marinović B, et al. European consensus-based (S2k) Guideline on the Management of Herpes Zoster - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 2: Treatment. J Eur Acad Dermatol Venereol. 2017 Jan;31(1):20-29. PMID: 27579792. PubMed
  18. John AR, Canaday DH. Herpes Zoster in the Older Adult. Infect Dis Clin North Am. 2017;31(4):811-826. PMID: 29079160 PubMed
  19. Chen N, Li Q, Yang J, et al. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2014;2:CD006866. PMID: 24500927 pubmed.ncbi.nlm.nih.gov
  20. Pasternak B, Hviid A. Use of acyclovir, valacyklovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. JAMA 2010; 304: 859-66. Journal of the American Medical Association
  21. Statens legemiddelverk. Riktigere bruk av NSAIDs. Terapiråd til helsepersonell, utarbeidet i samarbeid med RELIS. Publisert 21.09.2016. Siden lest 30.03.2023. legemiddelverket.no
  22. Schmader K. Herpes Zoster. Ann Intern Med. 2018 Aug 7;169(3):ITC19-ITC31. doi: 10.7326/AITC201808070. Erratum in: Ann Intern Med. 2018 Oct 2;169(7):516. PMID: 30083718 PubMed
  23. Han Y, Zhang J, Chen N, He L, Zhou M, Zhu C. Corticosteroids for preventing postherpetic neuralgia. Cochrane Database of Systematic Reviews 2013, Issue 3. Art. No.: CD005582. DOI: 10.1002/14651858.CD005582.pub4. DOI
  24. Colin J, Prisant O, Cochener B, Lescale O, Rolland B, Hoang-Xuan T. Comparison of the efficacy and safety of valaciclovir and acyclovir for the treatment of herpes zoster ophthalmicus. Br J Ophthalmol 2000; 107: 1507-11. PubMed
  25. Jiang X, Li Y, Chen N, et al. Corticosteroids for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2023; 12: CD005582. pmid:38050854 PubMed
  26. de Oliveira Gomes J, Gagliardi AM, Andriolo BN et.al. Vaccines for preventing herpes zoster in older adults. Cochrane Database Syst Rev. 2023 Oct 2;PMID: 37781954 Publisert 02102023. Siden lest 18032024 The Cochrane Library
  27. Breuer J, Pacoud M, Gauthier A, Brown MM. Herps zoster as a risk factor for stroke and TIA. Neurology 2014. doi:10.1212/WNL.0000000000000038 DOI
  28. Alper BS, Lewis PR. Does treatment of Acute Herpes Zoster Prevent or Shorten Postherpetic Neuralgia? A Systematic Review of the Literature. J Fam Pract 2000, 49;3:255-64.
Annonse
Annonse